We also retrieved the TCGA project data [7] via the cBio Cancer Genomics Portal [8]; SLC6A3 mRNA expression levels (RNA Seq V2 RSEM) were overexpressed in a subgroup of 5 % of the ccRCC samples and patients with high SLC6A3 expression in the tumor tissue had a shorter period of overall survival (median period of survival 40 vs. 75 months); See Additional file 1: Figure S2. The gene discussed is SLC6A3; the disease is nonpapillary renal cell carcinoma.